MF59™-adjuvanted subunit influenza vaccine: an improved interpandemic influenza vaccine for vulnerable populations

References

• Simonsen L, Fukuda K, Schonberger LB, Cox NJ. The impact of influenza epidemics on hospitalizations. J. Infect. Dis.181, 831–837 (2000).
   PubMed Web of Science ®Google Scholar
• Recommended composition of influenza virus vaccines for use in the 2007–2008 influenza season. Wkly Epidemiol. Rec.82, 69–74 (2007).
   PubMedGoogle Scholar
• Goronzy JJ, Fulbright JW, Crowson CS, Poland GA, O’Fallon WM, Weyand CM. Value of immunological markers in predicting responsiveness to influenza vaccination in elderly individuals. J. Virol.75, 12182–12187 (2001).
   PubMed Web of Science ®Google Scholar
• Puig-Barbera J, Marquez CS. Effectiveness of influenza vaccine in the elderly. A critical review of the bibliography. Med. Clin. (Barc)105, 645–648 (1995).
   PubMed Web of Science ®Google Scholar
• Vu T, Farish S, Jenkins M, Kelly H. A meta-analysis of effectiveness of influenza vaccine in persons aged 65 years and over living in the community. Vaccine20, 1831–1836 (2002).
   PubMed Web of Science ®Google Scholar
• Thompson WW, Shay DK, Weintraub E et al. Influenza-associated hospitalizations in the United States. JAMA292, 1333–1340 (2004).
   PubMed Web of Science ®Google Scholar
• Glezen WP, Greenberg SB, Atmar RL, Piedra PA, Couch RB. Impact of respiratory virus infections on persons with chronic underlying conditions. JAMA283, 499–505 (2000).
   PubMed Web of Science ®Google Scholar
• Lin JC, Nichol KL. Excess mortality due to pneumonia or influenza during influenza seasons among persons with acquired immunodeficiency syndrome. Arch. Intern. Med.161, 441–446 (2001).
   PubMedGoogle Scholar
• Podda A, Del Giudice G. MF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile. Expert Rev. Vaccines2, 197–203 (2003).
   PubMedGoogle Scholar
• Del Giudice G, Fragapane E, Bugarini R et al. Vaccines with the MF59 adjuvant do not stimulate antibody responses against squalene. Clin. Vaccine Immunol.13, 1010–1013 (2006).
   PubMed Web of Science ®Google Scholar
• D’Agosto V, Beradi S, Burroni D, Henning R. Tolerabiliy and safety of an MF59-adjuvanted subunit influenza vaccine (Fluad®). Presented at: Influenza Vaccines for the World Congress, Vienna, Austria, October 18–20 2006.
   Google Scholar
• Minutello M, Senatore F, Cecchinelli G et al. Safety and immunogenicity of an inactivated subunit influenza virus vaccine combined with MF59 adjuvant emulsion in elderly subjects, immunized for three consecutive influenza seasons. Vaccine17, 99–104 (1999).
   PubMed Web of Science ®Google Scholar
• Menegon T, Baldo V, Bonello C, Dalla CD, Di Tommaso A, Trivello R. Influenza vaccines: antibody responses to split virus and MF59-adjuvanted subunit virus in an adult population. Eur. J. Epidemiol.15, 573–576 (1999).
   PubMed Web of Science ®Google Scholar
• De Donato S, Granoff D, Minutello M et al. Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly. Vaccine17, 3094–3101 (1999).
   PubMed Web of Science ®Google Scholar
• Baldo V, Menegon T, Bonello C, Floreani A, Trivello R. Comparison of three different influenza vaccines in institutionalised elderly. Vaccine19, 3472–3475 (2001).
   PubMed Web of Science ®Google Scholar
• Squarcione S, Sgricia S, Biasio LR, Perinetti E. Comparison of the reactogenicity and immunogenicity of a split and a subunit-adjuvanted influenza vaccine in elderly subjects. Vaccine21, 1268–1274 (2003).
   PubMed Web of Science ®Google Scholar
• Baldo V, Menegon T, Buoro S et al. Vaccination against influenza in the elderly. Experience with adjuvanted vaccines. Ann. Ig.11, 369–374 (1999).
   PubMedGoogle Scholar
• Pregliasco F, Mensi C, Serpilli W, Speccher L, Masella P, Belloni A. Immunogenicity and safety of three commercial influenza vaccines in institutionalized elderly. Aging (Milano)13, 38–43 (2001).
   PubMedGoogle Scholar
• Ruf BR, Colberg K, Frick M, Preusche A. Open, randomized study to compare the immunogenicity and reactogenicity of an influenza split vaccine with an MF59-adjuvanted subunit vaccine and a virosome-based subunit vaccine in elderly. Infection32, 191–198 (2004).
   PubMed Web of Science ®Google Scholar
• Banzhoff A, Nacci P, Podda A. A new MF59-adjuvanted influenza vaccine enhances the immune response in the elderly with chronic diseases: results from an immunogenicity meta-analysis. Gerontology49, 177–184 (2003).
   PubMed Web of Science ®Google Scholar
• de Roux A, Marx A, Burkhardt O et al. Impact of corticosteroids on the immune response to a MF59-adjuvanted influenza vaccine in elderly COPD-patients. Vaccine24, 1537–1542 (2006).
   PubMed Web of Science ®Google Scholar
• Baldo V, Baldovin T, Floreani A, Carraro AM, Trivello R. MF59-adjuvanted influenza vaccine confers superior immunogenicity in adult subjects (18–60 years of age) with chronic diseases who are at risk of post-influenza complications. Vaccine25, 3955–3961 (2007).
   PubMed Web of Science ®Google Scholar
• Iorio AM, Francisci D, Camilloni B et al. Antibody responses and HIV-1 viral load in HIV-1-seropositive subjects immunised with either the MF59-adjuvanted influenza vaccine or a conventional nonadjuvanted subunit vaccine during highly active antiretroviral therapy. Vaccine21, 3629–3637 (2003).
   PubMed Web of Science ®Google Scholar
• Del Giudice G, Hilbert AK, Bugarini R et al. An MF59-adjuvanted inactivated influenza vaccine containing A/Panama/1999 (H3N2) induced broader serological protection against heterovariant influenza virus strain A/Fujian/2002 than a subunit and a split influenza vaccine. Vaccine24, 3063–3065 (2006).
   PubMed Web of Science ®Google Scholar
• Baldo V, Baldovin T, Floreani A, Fragapane E, Trivello R. Response of influenza vaccines against heterovariant influenza virus strains in adults with chronic diseases. J. Clin. Immunol.27, 542–547 (2007).
   PubMed Web of Science ®Google Scholar
• Puig-Barbera J, Diez-Domingo J, Perez HS, Belenguer VA, Gonzalez VD. Effectiveness of the MF59-adjuvanted influenza vaccine in preventing emergency admissions for pneumonia in the elderly over 64 years of age. Vaccine23, 283–289 (2004).
   PubMed Web of Science ®Google Scholar
• Puig-Barbera J, Diez-Domingo J, Beleguer-Varea A et al. Effectiveness of MF59TM-adjuvanted subunit influenza vaccine in preventing hospitalisations for cardiovascular disease, cerebrovascular disease and pneumonia in the elderly. Vaccine https://doi.org/10.1016/j.vaccine.2007.08.039 doi:10.1016/j.vaccine.2007.08.039 (2007).
   Google Scholar
• European Influenza Surveillance Scheme. Annual Report: 2004–2005 Influenza Season. NIVEL, Utrecht, The Netherlands (2006).
   Google Scholar
• Iob A, Brianti G, Zamparo E, Gallo T. Evidence of increased clinical protection of an MF59-adjuvant influenza vaccine compared to a nonadjuvant vaccine among elderly residents of long-term care facilities in Italy. Epidemiol. Infect.133, 687–693 (2005).
   PubMed Web of Science ®Google Scholar
• Francia F, Todeschini R, Mezzetti F, Rangoni R, Pandolfi P. Preliminary evaluations on the incidence of influenza-like illness in 2005 among populations of Emilia-Romanga, Italy, who received different flu vaccines. Presented at: 12th ICID Congress, Lisbon, Portugal, June 15–18 2006.
   Google Scholar
• Campins Martí M, Farjas Abadía P, González Vidal D. Modelo farmaeconómico de vacunación antigripal en población mayor de 64 años. Vacunas4(Suppl. 1), 35–41 (2003).
   Google Scholar
• Baio G, Pammolli F, Baldo V, Trivello R. Object-oriented influence diagram for cost–effectiveness analysis of influenza vaccination in the Italian elderly population. Expert Rev. Pharmacoeconomics Outcomes Res.6, 293–301 (2006).
   PubMedGoogle Scholar
• Piercy J, Ryan J, Megas F. Economic evaluation of MF59 adjuvanted vaccine against influenza in the high-risk elderly population in France. J. Med. Economics7, 1–18 (2004).
   Google Scholar
• Lasky T, Terracciano GJ, Magder L et al. The Guillain–Barre syndrome and the 1992–1993 and 1993–1994 influenza vaccines. N. Engl. J. Med.339, 1797–1802 (1998).
   PubMed Web of Science ®Google Scholar
• Jefferson T. Influenza vaccination: policy versus evidence. Br. Med. J.333, 912–915 (2006).
   PubMed Web of Science ®Google Scholar
• Freedman B. Equipoise and the ethics of clinical research. N. Engl. J. Med.317, 141–145 (1987).
   PubMed Web of Science ®Google Scholar
• Als-Nielsen B, Chen W, Gluud C, Kjaergard LL. Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events? JAMA290, 921–928 (2003).
   PubMed Web of Science ®Google Scholar